Table 1

 Patient characteristics in (A) the infliximab trial and (B) the etanercept trial

CharacteristicActive drugPlacebo
In the infliximab trial, the baseline characteristics of the two treatment groups showed no significant differences.
*p<0.05 calculated by the Wilcoxon rank sum test between groups; all other baseline characteristics of the groups in the etanercept trial showed no significant differences.
BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; BASRI-s, Bath ankylosing spondylitis radiology index of the spine; VAS, visual analogue scale.
(A) Infliximab trial
n3435
Male/female ratio23/1122/13
Age (years) (mean (SD))40.6 (8.0)39.0 (9.1)
Disease duration (years) (mean (SD))16.4 (8.3)14.9 (9.3)
HLA-B27 positive (%)31 (91.2)27 (87.5)
Number of swollen joints, range 0–68 (5% trimmed mean (SD))0.9 (4.1)1.3 (5.2)
Number of enthesitic regions, range 0–12 (mean (SD))1.7 (3.3)2.0 (3.2)
History of anterior uveitis (%)17 (50)15 (43)
BASDAI (mean (SD))6.5 (1.2)6.3 (1.4)
BASFI (mean (SD))5.4 (1.8)5.1 (2.2)
BASMI (mean (SD))3.7 (2.0)3.7 (2.2)
Pain (VAS) (mean (SD))7.2 (1.6)7.3 (1.7)
Radiological score for spine (BASRI-s) (mean (SD))6.5 (2.5)6.6 (2.9)
(B) Etanercept trial
n1416
Male/female ratio10/412/4
Age* (years) (mean (SD))39.8 (9.1)32.0 (7.5)
Disease duration (years) (mean (SD))14.9 (8.3)11.4 (8.8)
HLA-B27 positive (%)12 (85.7)15 (93.8)
Number of swollen joints, range 0–68 (mean (SD) at baseline)0.9 (1.5)1.7 (4.0)
Number of enthesitic regions, range 0–12 (mean (SD) at baseline)1.4 (2.2)1.3 (1.7)
History of anterior uveitis (n (%))5 (35.7)3 (18.8)
BASDAI (mean (SD))6.5 (1.2)6.6 (1.0)
BASFI (mean (SD))6.2 (1.8)5.3 (2.3)
BASMI (mean (SD))4.1 (1.7)3.8 (2.1)
Pain (VAS) (mean (SD))7.4 (1.8)7.6 (1.2)
Radiological score for spine (BASRI-s) (mean (SD))6.3 (2.5)5.4 (1.7)